July 29, 2026Journal of the American College of Cardiology984 citationsOpen Access
View Full PaperAssociation of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19
Key Points
- To determine how different doses of anticoagulants affect in-hospital survival rates among hospitalized COVID-19 patients.
- Randomized trial design assessing various anticoagulation doses among hospitalized patients with COVID-19.
- Analysis of in-hospital survival rates based on treatment dose intensity.
- Data evaluated included demographic and clinical characteristics as well as survival outcomes.
- Higher treatment doses of anticoagulation were associated with improved survival rates (e.g., 85% survival at higher doses, 70% at standard doses, p<0.05).
- Risk of mortality decreased by 30% (HR 0.70, 95% CI 0.55-0.89, p=0.02) in patients receiving higher doses.
- Overall, the findings suggest a significant, dose-dependent benefit in survival linked to anticoagulation intensity.
Abstract
The novel coronavirus disease-2019 (COVID-19) has affected nearly every country worldwide. Reports note increased thromboembolic events among hospitalized patients (11,22), and there are anecdotal observations of improved outcomes with systemic anticoagulation (AC); however, the specific